By all means wave the pom-poms but what this announcement avoids is things like the fact the warmth study patients were older, had higher PSA, more lung and liver metastases than Lupin patients and the real gem for me, warmth median only 3 cycles Lu vs median 5 cycles Lu in lupin. So less treatment in Warmth with the lutetium. not well matched groups after all it seems
so yes I stick with my view this isn’t a valid comparison and trumpeting 71% survival improvement with Nox is pretty poor science and BS - imo.
- Forums
- ASX - By Stock
- Ann: New Independent Trial Data Supports Potential of Veyonda
By all means wave the pom-poms but what this announcement avoids...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
0.010(14.3%) |
Mkt cap ! $23.37M |
Open | High | Low | Value | Volume |
7.0¢ | 8.0¢ | 7.0¢ | $4.207K | 56.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 118527 | 7.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 4999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 118527 | 0.075 |
2 | 14000 | 0.067 |
1 | 141114 | 0.066 |
1 | 100000 | 0.064 |
1 | 77000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 4999 | 1 |
0.081 | 22345 | 2 |
0.083 | 40000 | 1 |
0.090 | 25689 | 3 |
0.092 | 5555 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online